For the quarter ending 2025-09-30, ACRV made $21,199K in revenue. -$18,228K in net income. Net profit margin of -85.99%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 13,648 | 16,182 | ||
| General and administrative | 6,039 | 6,467 | ||
| Total operating expenses | 19,687 | 22,649 | ||
| Loss from operations | -19,687 | -22,649 | ||
| Interest income | 1,506 | 1,730 | ||
| Other (expense) income, net | -53 | -87 | ||
| Total other income, net | 1,453 | 1,643 | ||
| Net loss | -18,234 | -21,006 | ||
| Unrealized gain (loss) on available-for-sale investments, net of tax | 6 | -177 | ||
| Comprehensive loss | -18,228 | -21,183 | ||
| Net loss per sharebasic | -0.47 | -0.55 | ||
| Net loss per sharediluted | -0.47 | -0.55 | ||
| Weighted-average common stock outstandingbasic | 38,560,464 | 38,461,619 | ||
| Weighted-average common stock outstandingdiluted | 38,560,464 | 38,461,619 | ||
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)